Abstract
Background: Among CRC patients with mismatch repair protein deficiency or microsatellite instability (MSI), up to 50% of cases lack germline mutations in MMR genes, BRAF mutations, or MLH1 promoter methylation. Such cases are defined as Lynch-like syndrome (LLS). LLS is a heterogeneous group of diseases that may include both sporadic and hereditary cases. Although various methods have been proposed to distinguish between hereditary and sporadic cases, there is still a lack of consensus on the precise classification of these patients. Methods: Four cases of Lynch-like syndrome encountered in daily clinical pathological diagnostic work were reported. The histopathological characteristics and molecular pathological changes of related tumors were analyzed, and the diagnosis and treatment progress of this disease were reviewed via literature. Results: Lynch-like syndrome-related tumors can occur in the colorectum and extraintestinal organs. Colorectal tumors show no specific locational or histological features, while extraintestinal tumors often exhibit poor differentiation and abundant interstitial lymphocyte infiltration. Patients with Lynch-like syndrome all exhibit tumoral lesions with loss of MMR protein (MLH1, PMS2, MSH2, MSH6) expression, microsatellite instability (MSI-L/MSI-H), wild-type BRAF, and negative MLH1 promoter methylation. However, heterogeneity exists in MMR protein expression, MSI status, and MLH1 promoter methylation among tumors at different sites in the same patient. No germline pathogenic mutations in MMR genes were detected in any patient, but two cases showed suspected pathogenic mutations in MLH1, and one case had a variant of uncertain significance in PMS2. Conclusion: Extraintestinal tumors associated with Lynch-like syndrome mostly exhibit histopathological characteristics and MMR/MSI changes similar to classic Lynch syndrome, but without pathogenic germline MMR mutations or MLH1 promoter methylation. Some Lynch-like syndromes with suspected germline pathogenic MMR mutations may represent Lynch syndrome with rare mutation types. Most cases lack germline MMR mutations in normal tissues but harbor somatic MMR mutations in tumor tissues. Germline or somatic mutations in other genes related to MMR function may be observed in some cases.
Introduction
Lynch Syndrome (LS) is a well-characterized hereditary condition resulting from germline mutations in DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2). However, clinical practice frequently encounters patients with mismatch repair deficiency (dMMR) or microsatellite instability (MSI) who do not meet the genetic criteria for LS—specifically, they lack germline MMR mutations, BRAF mutations, and MLH1 promoter methylation. These cases are categorized as Lynch-like Syndrome (LLS).
LLS represents a diagnostic challenge, as it encompasses a heterogeneous group of both sporadic and potentially hereditary conditions. Without a clear consensus on classification, clinicians struggle to determine if these patients (and their families) require the intensive surveillance associated with hereditary syndromes or the standard care for sporadic cancers.
Methods
The study analyzed four LLS cases using a multi-modal diagnostic framework. Histopathological features were assessed via HE staining, while MMR protein expression (MLH1, PMS2, MSH2, MSH6) was evaluated using immunohistochemistry (IHC). Microsatellite status was determined through fluorescence quantitative PCR-capillary electrophoresis. To exclude sporadic cases driven by epigenetic silencing, MLH1 promoter methylation was analyzed via quantitative real-time PCR. Finally, Next-Generation Sequencing (NGS) was employed to identify both germline and somatic mutations in MMR genes and other relevant drivers like POLE and TP53.
Results and Case Analysis
The molecular profiles of the four cases are summarized in the table below, highlighting the diversity of genetic drivers found in this cohort.
The analysis revealed two primary subgroups within the LLS cohort:
- Sporadic LLS (Cases 1 & 2): These cases were driven by acquired somatic events. Case 1 featured a somatic pathogenic mutation in MSH2 within the tumor without a corresponding germline mutation, effectively explaining the dMMR phenotype as a sporadic event. Case 2 was particularly notable for a POLE mutation. POLE proofreading deficiency can lead to secondary MMR failure, illustrating that LLS can be a downstream consequence of other genomic instabilities. Furthermore, Case 2 exhibited intra-patient heterogeneity, with different tumors showing varying MSI statuses (MSI-L vs. MSS).
- Hereditary LLS (Cases 3 & 4): These cases involved suspected germline MLH1 mutations. While not definitively classified as classic Lynch Syndrome under current standards, the authors suggest these may represent rare or complex germline variants that are currently under-recognized or classified as "variants of uncertain significance" (VUS).
Discussion
The findings underscore that LLS is not a single disease entity but a "catch-all" for diverse molecular pathways. The identification of somatic "double hits" in MMR genes or mutations in genes like POLE can help reclassify some LLS patients as sporadic, potentially sparing their families from intensive hereditary cancer surveillance.
Conversely, the presence of suspected germline variants in cases like 3 and 4 highlights the limitations of current genetic screening. Some LLS cases may indeed be Lynch Syndrome variants that require more advanced sequencing techniques, such as those capable of detecting deep intronic mutations or complex structural inversions (e.g., MSH2 inversions).
Conclusion
Extraintestinal tumors in LLS often mirror the histopathological characteristics of classic LS, including poor differentiation and high lymphocyte infiltration. Distinguishing between sporadic and hereditary LLS is critical for clinical management. While many cases are driven by somatic mutations, others likely harbor rare germline variants. Future work should focus on standardizing classification protocols and integrating comprehensive family pedigree analysis with advanced molecular testing to provide clearer guidance for patients and their families.
Summary updated